Construction of a tetR-integrated Salmonella enterica serovar typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium falciparum for applications in human vaccine production

Infection and Immunity

Volumn 70, Issue 4, 2002, Pages 2029-2038

  Qian, Feng ^a   Pan, Weiqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CRE RECOMBINASE; GENE PRODUCT; KANAMYCIN; LUCIFERASE; MEROZOITE SURFACE PROTEIN 1; NEO PROTEIN; PLASMID VECTOR; SALMONELLOSIS VACCINE; SALMONELLOSIS VACCINE CVD908 TETR; TETR PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE SEGREGATION; GENETIC STABILITY; GENETIC TRANSFORMATION; IMMUNOGENICITY; LIVER; MEROZOITE; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPRESSOR GENE; SALMONELLA ENTERICA; SALMONELLA TYPHI; SEROTYPE; SPLEEN; STRAIN IDENTIFICATION; VACCINE PRODUCTION;

ANIMALS; FEMALE; HUMANS; INTEGRASES; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; PLASMIDS; PLASMODIUM FALCIPARUM; REPRESSOR PROTEINS; SALMONELLA TYPHI; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 0036127033     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.4.2029-2038.2002     Document Type: Article

References (50)

1. + cytotoxic T cells
2. Plasmodium vivax: Exoerythrocytic schizonts recognized by monoclonal antibodies against blood-stage schizonts
3. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908
4. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies
5. Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors
6. Introduction of protein or DNA delivered via recombinant Salmonella typhimurium into the major histocompatibility complex class I presentation pathway of macrophages
7. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: Development of a single-dose oral tetanus vaccine
8. Merozoite surface antigen-1 of Plasmodium
9. Use of in vivoregulated promoters to deliver antigens from attenuated Salmonella enterica var
10. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum
11. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens
12. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA
13. Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain
14. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: Strain construction and safety and immunogenicity in humans
15. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana
16. Transcriptional activation by tetracyclines in mammalian cells
17. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies
18. Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria
19. Macrophage-inducible expression of a model antigen in Salmonella typhimurium enhances immunogenicity
20. Immunization against blood-stage rodent malaria using purified parasite antigens
21. Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum
22. Construction of genetically defined double aro mutants of Salmonella typhi
23. Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1
24. Site-specific recombinases: Tools for genome engineering
25. Immunogenicity and efficacy in Aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1
26. Plasmodium falciparum: gp195 tripeptide repeat-specific monoclonal antibody inhibits parasite growth in vitro
27. Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA
28. Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements
29. Merozoite surface protein-1 epitopes recognized by antibodies that inhibit Plasmodium falciparum merozoite dispersal
30. Passive immunization against murine malaria with an IgG3 monoclonal antibody
31. Modulation of host immune responses stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen
32. + expression-cloning vector: Stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain
33. Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA
34. Vaccine candidate MSP-1 from Plasmodium falciparum: A redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells
35. Antimalarial immunity in Saimiri monkeys. Immunization with surface components of asexual blood stages
36. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors
37. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria
38. Expression of the merozoite surface protein gp195 in vaccinia virus
39. Recent advances with recombinant bacterial vaccine vectors
40. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria
41. Live attenuated Salmonella: A paradigm of mucosal vaccines
42. Bacteriophage P1 cre gene and its regulatory region. Evidence for multiple promoters and for regulation by DNA methylation
43. Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains
44. System for high level production in E. coli and rapid purification of recombinant proteins: Application to epitope mapping, preparation of antibodies and structure-function analysis
45. Expression of the precursor of the major merozoite surface antigens during the hepatic stage of malaria
46. Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stages
47. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans
48. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers
49. Cre/loxP-mediated excision and amplification of large segments of the Escherichia coli genome